ReviewCellular and molecular life sciences : CMLS2026
Harnessing the power of the gut microbiome: a review of supplementation diagnosis and therapy for liver cirrhosis.
Review in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Liver cirrhosis is an end-stage pathological process caused by various chronic liver diseases, whose incidence is increasing and represents a serious public health burden. The onset of liver cirrhosis is related to various factors such as alcohol, autoimmune, steatosis, and viral infections. Recent research suggests that the gut microbiota also participates in the progression of liver cirrhosis and that supplementation with probiotics improves the progression of liver diseases. We have reviewed the latest studies on the mutual influence between the gut microbiota (including bacteria, fungi and virus) and cirrhosis, and summarized the changes in the gut microbiota, the immune and metabolic mechanisms, and the application of gut microbiota in the clinical management, hoping to provide new strategies for the diagnosis and treatment of liver cirrhosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.